Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

Abstract Introduction While [177 Lu] Lu-PSMA radioligand therapy is currently only applied
in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Abstract Background Dosimetry in [177Lu] Lu-PSMA therapy is a valuable tool to assess
treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol …

Abstract Introduction Patient eligibility for [177 Lu] Lu-PSMA therapy remains a challenge,
with only 40–60% response rate when patient selection is done based on the lesion uptake …

Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …

Radionuclide therapy using the small molecule PSMA bound to the beta-emitting
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …